Dr.NEET MEHTA

DR. SUNITA CHAURASIA, DR. MURALEEDHARA R.

Abstract

This is a prospective, placebo-controlled, paired eye clinical trial exploring role of topical Nepafenac eye drop in cases of Congenital Hereditary Endothelial Dystrophy (CHED). 30 eyes of 15 children with CHED were analyzed. Topical Nepafenac was administered four times a day for six months in the study eyes, while preservative-free lubricants were used in the control eyes. All subjects underwent an ophthalmic examination and anterior imaging including corneal densitometry. At a median follow-up of 5.9 months, corneal densitometry showed a statistically significant reduction in the anterior, central and posterior layers in the test eyes with a P < 0.0001. There were no adverse events noted due to the use of topical NSAIDs. Thus, showing the potential role of topical NSAIDs in the CHED cohort. This would translate into much less risk of amblyopia and definitive intervention like DSAEK could be delayed, thus maximizing the functional success of surgical interventions.